Oral nitrate supplementation to enhance pulmonary rehabilitation in COPD: ON-EPIC a multicentre, double-blind, placebo-controlled, randomised parallel group study.


Journal

Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353

Informations de publication

Date de publication:
07 2020
Historique:
received: 31 10 2019
revised: 23 03 2020
accepted: 15 04 2020
pubmed: 8 5 2020
medline: 20 8 2020
entrez: 8 5 2020
Statut: ppublish

Résumé

Dietary nitrate supplementation has been proposed as a strategy to improve exercise performance, both in healthy individuals and in people with COPD. We aimed to assess whether it could enhance the effect of pulmonary rehabilitation (PR) in COPD. This double-blind, placebo-controlled, parallel group, randomised controlled study performed at four UK centres, enrolled adults with Global Initiative for Chronic Obstructive Lung Disease grade II-IV COPD and Medical Research Council dyspnoea score 3-5 or functional limitation to undertake a twice weekly 8-week PR programme. They were randomly assigned (1:1) to either 140 mL of nitrate-rich beetroot juice (BRJ) (12.9 mmol nitrate), or placebo nitrate-deplete BRJ, consumed 3 hours prior to undertaking each PR session. Allocation used computer-generated block randomisation. The primary outcome was change in incremental shuttle walk test (ISWT) distance. Secondary outcomes included quality of life, physical activity level, endothelial function via flow-mediated dilatation, fat-free mass index and blood pressure parameters. 165 participants were recruited, 78 randomised to nitrate-rich BRJ and 87 randomised to placebo. Exercise capacity increased more with active treatment (n=57) than placebo (n=65); median (IQR) change in ISWT distance +60 m (10, 85) vs +30 m (0, 70), estimated treatment effect 30 m (95% CI 10 to 40); p=0.027. Active treatment also impacted on systolic blood pressure: treatment group -5.0 mm Hg (-5.0, -3.0) versus control +6.0 mm Hg (-1.0, 15.5), estimated treatment effect -7 mm Hg (95% CI 7 to -20) (p<0.0005). No significant serious adverse events or side effects were reported. Dietary nitrate supplementation appears to be a well-tolerated and effective strategy to augment the benefits of PR in COPD. ISRCTN27860457.

Identifiants

pubmed: 32376732
pii: thoraxjnl-2019-214278
doi: 10.1136/thoraxjnl-2019-214278
doi:

Substances chimiques

Nitrates 0

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

547-555

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Matthew J Pavitt (MJ)

National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.

Rebecca Jayne Tanner (RJ)

National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.

Adam Lewis (A)

National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.

Sara Buttery (S)

National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.

Bhavin Mehta (B)

Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Helen Jefford (H)

Greenwich Adult Community Health Service, Oxleas NHS Foundation Trust, Dartford, Kent, UK.

Katrina J Curtis (KJ)

National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.

Winston A S Banya (WAS)

National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.

Syed Husain (S)

Respiratory Medicine, Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, UK.

Karnan Satkunam (K)

Greenwich Adult Community Health Service, Oxleas NHS Foundation Trust, Dartford, Kent, UK.

Dinesh Shrikrishna (D)

Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust, Taunton, Somerset, UK.

William Man (W)

National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.
Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Michael I Polkey (MI)

National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK.
Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.

Nicholas S Hopkinson (NS)

National Heart and Lung Institute, Royal Brompton Campus, Imperial College London, London, UK n.hopkinson@ic.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH